
Giuseppe Gerna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/457593/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Slow cytomegalovirusâ€specific CD4 ⁺ and CD8 ⁺ Tâ€cell differentiation: 10â€year followâ€up of primary infection in a small number of immunocompetent hosts. European Journal of Immunology, 2021, 51, 253-256.	2.9	2
2	Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Journal of Clinical Virology, 2021, 135, 104734.	3.1	5
3	Detection of Genotype-Specific Antibody Responses to Glycoproteins B and H in Primary and Non-Primary Human Cytomegalovirus Infections by Peptide-Based ELISA. Viruses, 2021, 13, 399.	3.3	4
4	Congenital Human Cytomegalovirus Infection: A Narrative Review of Maternal Immune Response and Diagnosis in View of the Development of a Vaccine and Prevention of Primary and Non-Primary Infections in Pregnancy. Microorganisms, 2021, 9, 1749.	3.6	10
5	Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development. Vaccines, 2020, 8, 194.	4.4	7
6	Analysis of the SARS-CoV-2 epidemic in Italy: The role of local and interventional factors in the control of the epidemic. PLoS ONE, 2020, 15, e0242305.	2.5	10
7	An overview of letermovir: a cytomegalovirus prophylactic option. Expert Opinion on Pharmacotherapy, 2019, 20, 1429-1438.	1.8	17
8	Brief molecular diagnostic criteria for human cytomegalovirus infection/disease. Expert Review of Molecular Diagnostics, 2019, 19, 773-775.	3.1	2
9	Human Cytomegalovirus Cell Tropism and Host Cell Receptors. Vaccines, 2019, 7, 70.	4.4	61
10	Determination of anti-p52 IgM and anti-gB IgG by ELISA as a novel diagnostic tool for detection of early and late phase of primary human cytomegalovirus infections during pregnancy. Journal of Clinical Virology, 2019, 120, 38-43.	3.1	4
11	Human Cytomegalovirus Genomes Sequenced Directly From Clinical Material: Variation, Multiple-Strain Infection, Recombination, and Gene Loss. Journal of Infectious Diseases, 2019, 220, 781-791.	4.0	84
12	Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. New Microbiologica, 2019, 42, 1-20.	0.1	32
13	Human cytomegalovirus (HCMV)â€specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solidâ€organ transplant recipients. Journal of Medical Virology, 2018, 90, 1620-1628.	5.0	21
14	Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. Reviews in Medical Virology, 2017, 27, e1921.	8.3	40
15	The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development. Journal of General Virology, 2017, 98, 2215-2234.	2.9	30
16	Phenotype and specificity of T cells in primary human cytomegalovirus infection during pregnancy: IL-7Rpos long-term memory phenotype is associated with protection from vertical transmission. PLoS ONE, 2017, 12, e0187731.	2.5	21
17	Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Immunotherapy, 2016, 8, 1135-1149.	2.0	11
18	Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation. Journal of Virology, 2016, 90, 6216-6223.	3.4	63

#	Article	IF	CITATIONS
19	Neutralizing and ELISA IgG antibodies to human cytomegalovirus glycoprotein complexes may help date the onset of primary infection in pregnancy. Journal of Clinical Virology, 2016, 81, 16-24.	3.1	17
20	Comparative magnitude and kinetics of human cytomegalovirusâ€specific CD4 ⁺ and CD8 ⁺ Tâ€cell responses in pregnant women with primary versus remote infection and in transmitting versus nonâ€transmitting mothers: Its utility for dating primary infection in pregnancy. Journal of Medical Virology, 2016, 88, 1238-1246.	5.0	31
21	Follicular helper T-cells and virus-specific antibody response in primary and reactivated human cytomegalovirus infections of the immunocompetent and immunocompromised transplant patients. Journal of General Virology, 2016, 97, 1928-1941.	2.9	12
22	Sequencing and Analysis of Globally Obtained Human Respiratory Syncytial Virus A and B Genomes. PLoS ONE, 2015, 10, e0120098.	2.5	61
23	Prevention of Primary Cytomegalovirus Infection in Pregnancy. EBioMedicine, 2015, 2, 1205-1210.	6.1	170
24	Primary human cytomegalovirus infections: Kinetics of ELISA-IgG and neutralizing antibody in pauci/asymptomatic pregnant women vs symptomatic non-pregnant subjects. Journal of Clinical Virology, 2015, 64, 45-51.	3.1	16
25	Reconstitution of Human Cytomegalovirus–Specific CD4 + T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection. Biology of Blood and Marrow Transplantation, 2015, 21, 2192-2202.	2.0	36
26	Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. Journal of General Virology, 2015, 96, 360-369.	2.9	26
27	Human Cytomegalovirus (HCMV)-Specific CD4+ and CD8+ T Cells Are Both Required for Prevention of HCMV Disease in Seropositive Solid-Organ Transplant Recipients. PLoS ONE, 2014, 9, e106044.	2.5	42
28	Polyfunctional Analysis of Human Cytomegalovirus (HCMV)-Specific CD4+ and CD8+ Memory T-Cells in HCMV-Seropositive Healthy Subjects Following Different Stimuli. Journal of Clinical Immunology, 2014, 34, 999-1008.	3.8	6
29	Cytomegalovirus DNAemia in pregnant women. Journal of Clinical Virology, 2014, 61, 590-592.	3.1	32
30	Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17965-17970.	7.1	116
31	A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. Obstetrical and Gynecological Survey, 2014, 69, 388-390.	0.4	3
32	A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus. New England Journal of Medicine, 2014, 370, 1316-1326.	27.0	413
33	Hyperimmune Globulin to Prevent Congenital CMV Infection. New England Journal of Medicine, 2014, 370, 2543-2545.	27.0	37
34	Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. Journal of Medical Virology, 2013, 85, 1960-1967.	5.0	37
35	Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection. PLoS ONE, 2013, 8, e59863.	2.5	170
36	Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients. New Microbiologica, 2013, 36, 267-77.	0.1	9

#	Article	IF	CITATIONS
37	Endothelial cells and CMV dissemination. Future Microbiology, 2012, 7, 441-444.	2.0	7
38	Human rhinovirus and human respiratory enterovirus (EV68 and EV104) infections in hospitalized patients in Italy, 2008–2009. Diagnostic Microbiology and Infectious Disease, 2012, 73, 162-167.	1.8	48
39	Antibodies Against Neutralization Epitopes of Human Cytomegalovirus gH/gL/pUL128-130-131 Complex and Virus Spreading May Correlate with Virus Control In Vivo. Journal of Clinical Immunology, 2012, 32, 1324-1331.	3.8	87
40	Monitoring of Human Cytomegalovirus and Virus-Specific T-Cell Response in Young Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2012, 7, e41648.	2.5	53
41	Human parechovirus infections in patients admitted to hospital in Northern Italy, 2008–2010. Journal of Medical Virology, 2012, 84, 686-690.	5.0	44
42	Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients. New Microbiologica, 2012, 35, 279-87.	0.1	19
43	Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: A 20-year experience. Journal of Clinical Virology, 2011, 50, 303-307.	3.1	112
44	Serum antibody response to the gH/gL/pUL128–131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. Journal of Clinical Virology, 2011, 52, 113-118.	3.1	61
45	Heart rate and cardiac allograft vasculopathy in heart transplant recipients. Journal of Heart and Lung Transplantation, 2011, 30, 1368-1373.	0.6	22
46	Virologic and Immunologic Monitoring of Cytomegalovirus to Guide Preemptive Therapy in Solid-Organ Transplantation. American Journal of Transplantation, 2011, 11, 2463-2471.	4.7	85
47	Kinetics of Effector Functions and Phenotype of Virus-Specific and Î ³ δT Lymphocytes in Primary Human Cytomegalovirus Infection During Pregnancy. Journal of Clinical Immunology, 2011, 31, 1054-1064.	3.8	36
48	Phylogenetic Patterns of Human Respiratory Picornavirus Species, Including the Newly Identified Group C Rhinoviruses, during a 1-Year Surveillance of a Hospitalized Patient Population in Italy. Journal of Clinical Microbiology, 2011, 49, 373-376.	3.9	49
49	Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection. New Microbiologica, 2011, 34, 229-54.	0.1	22
50	Human cytomegalovirus-specific CD4+ and CD8+ T-cell response determination: Comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. Clinical Immunology, 2010, 136, 269-281.	3.2	9
51	Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Reviews in Medical Virology, 2010, 20, 136-155.	8.3	130
52	Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex. Journal of Virology, 2010, 84, 1005-1013.	3.4	299
53	Enterovirus Genotype EV-104 in Humans, Italy, 2008–2009. Emerging Infectious Diseases, 2010, 16, 1018-1021.	4.3	26
54	Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. Journal of Clinical Virology, 2010, 48, 255-259.	3.1	77

#	Article	IF	CITATIONS
55	Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. Journal of General Virology, 2010, 91, 1535-1546.	2.9	164
56	Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes. Journal of Virology, 2009, 83, 6323-6323.	3.4	2
57	HIV-1 Plasma Variants Encoding Truncated Reverse Transcriptase (RT) in a Patient With High RT-Specific CD8+ Memory T-Cell Response. Current HIV Research, 2009, 7, 302-310.	0.5	4
58	Are Human P[14] Rotavirus Strains the Result of Interspecies Transmissions from Sheep or Other Ungulates That Belong to the Mammalian Order <i>Artiodactyla</i> ?. Journal of Virology, 2009, 83, 2917-2929.	3.4	202
59	Human Cytomegalovirus–Specific T Cell Reconstitution in Young Patients Receiving T Cell–Depleted, Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2009, 199, 829-836.	4.0	28
60	Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients. American Journal of Transplantation, 2009, 9, 1142-1150.	4.7	39
61	Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clinical Immunology, 2009, 131, 395-403.	3.2	28
62	Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. Journal of Medical Virology, 2009, 81, 1498-1507.	5.0	100
63	Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. Haematologica, 2009, 94, 833-839.	3.5	38
64	Management of human cytomegalovirus infection in transplant recipients by the pre-emptive therapy approach. Future Virology, 2009, 4, 155-164.	1.8	1
65	Prophylaxis Versus Preemptive Therapy for Prevention of Human Cytomegalovirus Disease in Pediatric Liver Transplant Recipients. Transplantation, 2009, 87, 306-307.	1.0	Ο
66	Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiologica, 2009, 32, 245-53.	0.1	21
67	Surveillance of influenza virus B circulation in Northern Italy: summer-fall 2008 isolation of three strains and phylogenetic analysis. New Microbiologica, 2009, 32, 405-10.	0.1	1
68	Genotypic analysis of two hypervariable human cytomegalovirus genes. Journal of Medical Virology, 2008, 80, 1615-1623.	5.0	54
69	Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their families. Journal of Medical Virology, 2008, 80, 1415-1425.	5.0	36
70	Human cytomegalovirus load measurement and its applications for preâ€emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematological Oncology, 2008, 26, 123-130.	1.7	17
71	Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2008, 41, 873-879.	2.4	55
72	Monitoring human cytomegalovirus infection in transplant recipients. Journal of Clinical Virology, 2008, 41, 237-241.	3.1	74

#	Article	IF	CITATIONS
73	Comparison of a new Light Diagnosticsâ"¢ and the CMV Briteâ"¢ to an in-house developed human cytomegalovirus antigenemia assay. Journal of Clinical Virology, 2008, 43, 13-17.	3.1	3
74	Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. Journal of General Virology, 2008, 89, 853-865.	2.9	164
75	Maternal, fetal and neonatal diagnosis of congenital human cytomegalovirus infection. Expert Opinion on Medical Diagnostics, 2008, 2, 547-563.	1.6	10
76	Human Cytomegalovirus (HCMV) DNAemia in the Mother at Amniocentesis as a Risk Factor for latrogenic HCMV Infection of the Fetus. Journal of Infectious Diseases, 2008, 197, 593-596.	4.0	55
77	Human Cytomegalovirus–Specific Memory CD8 ⁺ and CD4 ⁺ T Cell Differentiation after Primary Infection. Journal of Infectious Diseases, 2008, 198, 536-543.	4.0	69
78	Response: Human cytomegalovirus DNAemia and preemptive treatment of HCMV infection in children receiving hematopoietic stem-cell transplantation. Blood, 2008, 111, 4420-4420.	1.4	0
79	Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica, 2008, 93, 248-256.	3.5	96
80	Prophylaxis Followed by Preemptive Therapy Versus Preemptive Therapy for Prevention of Human Cytomegalovirus Disease in Pediatric Patients Undergoing Liver Transplantation. Transplantation, 2008, 86, 163-166.	1.0	45
81	Development of Human Cytomegalovirus–Specific T Cell Immunity during Primary Infection of Pregnant Women and Its Correlation with Virus Transmission to the Fetus. Journal of Infectious Diseases, 2007, 195, 1062-1070.	4.0	108
82	Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood, 2007, 110, 2757-2760.	1.4	74
83	Quantification and identification of polyomavirus DNA in blood and urine of renal transplant recipients. Diagnostic Microbiology and Infectious Disease, 2007, 57, 301-307.	1.8	8
84	Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. Journal of Clinical Virology, 2007, 38, 244-250.	3.1	107
85	Human respiratory syncytial virus (hRSV) RNA quantification in nasopharyngeal secretions identifies the hRSV etiologic role in acute respiratory tract infections of hospitalized infants. Journal of Clinical Virology, 2007, 39, 119-124.	3.1	34
86	Prospective study of human metapneumovirus infection: Diagnosis, typing and virus quantification in nasopharyngeal secretions from pediatric patients. Journal of Clinical Virology, 2007, 40, 236-240.	3.1	23
87	NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine. Antiviral Research, 2007, 76, 99-103.	4.1	9
88	Inconsistent Responses of Cytomegalovirusâ€Specific T Cells to pp65 and IEâ€1 versus Infected Dendritic Cells in Organ Transplant Recipients. American Journal of Transplantation, 2007, 7, 1997-2005.	4.7	45
89	Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antiviral Therapy, 2007, 12, 63-72.	1.0	47
90	The human bocavirus role in acute respiratory tract infections of pediatric patients as defined by viral load quantification. New Microbiologica, 2007, 30, 383-92.	0.1	21

#	Article	IF	CITATIONS
91	Detection and pathogenicity of human metapneumovirus respiratory infection in pediatric Italian patients during a winter–spring season. Journal of Clinical Virology, 2006, 35, 59-68.	3.1	53
92	Simultaneous detection and typing of human metapneumovirus strains in nasopharyngeal secretions and cell cultures by monoclonal antibodies. Journal of Clinical Virology, 2006, 35, 113-116.	3.1	20
93	Prediction of endothelial cell tropism of human cytomegalovirus strains. Journal of Clinical Virology, 2006, 35, 470-473.	3.1	6
94	Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood, 2006, 108, 1406-1412.	1.4	88
95	Monitoring of Human Cytomegalovirus-Specific CD4+and CD8+T-Cell Immunity in Patients Receiving Solid Organ Transplantation. American Journal of Transplantation, 2006, 6, 2356-2364.	4.7	143
96	Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility. Antiviral Research, 2006, 69, 181-185.	4.1	11
97	Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. Journal of Medical Virology, 2006, 78, 408-416.	5.0	100
98	Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. Journal of Medical Virology, 2006, 78, 938-949.	5.0	156
99	Preconceptional Primary Human Cytomegalovirus Infection and Risk of Congenital Infection. Journal of Infectious Diseases, 2006, 193, 783-787.	4.0	62
100	Lymphoproliferative Response in Primary Human Cytomegalovirus (HCMV) Infection Is Delayed in HCMV Transmitter Mothers. Journal of Infectious Diseases, 2006, 193, 269-276.	4.0	62
101	Monitoring transplant patients for human cytomegalovirus: Diagnostic update. Herpes: the Journal of the IHMF, 2006, 13, 4-11.	0.3	11
102	Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. European Journal of Immunology, 2005, 35, 1795-1804.	2.9	66
103	Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. Journal of Medical Virology, 2005, 75, 336-347.	5.0	70
104	Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131–128 genes and mediates efficient viral antigen presentation to CD8+ T cells. Journal of General Virology, 2005, 86, 275-284.	2.9	185
105	Rapid Detection of Human Metapneumovirus Strains in Nasopharyngeal Aspirates and Shell Vial Cultures by Monoclonal Antibodies. Journal of Clinical Microbiology, 2005, 43, 3443-3446.	3.9	63
106	Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica, 2005, 90, 526-33.	3.5	28
107	Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrobial Agents and Chemotherapy, 2004, 48, 4611-4617.	3.2	20
108	Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. Journal of Antimicrobial Chemotherapy, 2004, 53, 536-539.	3.0	19

#	Article	IF	CITATIONS
109	Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes. Journal of Virology, 2004, 78, 10023-10033.	3.4	441
110	Dissociation of Serum and Liver Hepatitis C Virus RNA Levels in Patients Coinfected with Human Immunodeficiency Virus and Treated with Antiretroviral Drugs. Journal of Clinical Microbiology, 2004, 42, 3012-3016.	3.9	5
111	Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants. Journal of Antimicrobial Chemotherapy, 2004, 53, 766-771.	3.0	5
112	Clinical Evaluation of a Chemiluminescence Immunoassay for Determination of Immunoglobulin G Avidity to Human Cytomegalovirus. Vaccine Journal, 2004, 11, 801-805.	3.1	23
113	Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. Journal of Medical Virology, 2004, 73, 412-418.	5.0	36
114	Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. Journal of Clinical Virology, 2004, 29, 71-83.	3.1	133
115	Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Human Immunology, 2004, 65, 403-409.	2.4	78
116	Pathogenesis of human cytomegalovirus infection and cellular targets. Human Immunology, 2004, 65, 381-386.	2.4	105
117	Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients. Journal of Clinical Virology, 2004, 29, 297-307.	3.1	11
118	Assays for Determination of HIV Resistance to Antiviral Drugs. Current Drug Metabolism, 2004, 5, 317-319.	1.2	4
119	Genomes of the endothelial cell-tropic variant and the parental Toledo strain of human cytomegalovirus are highly divergent. Journal of Medical Virology, 2003, 69, 76-81.	5.0	15
120	Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. British Journal of Haematology, 2003, 122, 927-933.	2.5	42
121	Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. Journal of Clinical Virology, 2003, 26, 95-100.	3.1	23
122	A comparison of methods for detecting adenovirus type 8 keratoconjunctivitis during a nosocomial outbreak in a Neonatal Intensive Care Unit. Journal of Clinical Virology, 2003, 28, 257-264.	3.1	36
123	Nevirapine Resistance Mutation at Codon 181 of the HIV-1 Reverse Transcriptase Confers Stavudine Resistance by Increasing Nucleotide Substrate Discrimination and Phosphorolytic Activity. Journal of Biological Chemistry, 2003, 278, 15469-15472.	3.4	21
124	Prenatal Diagnosis of Congenital Human Cytomegalovirus Infection in Amniotic Fluid by Nucleic Acid Sequence-Based Amplification Assay. Journal of Clinical Microbiology, 2003, 41, 1772-1774.	3.9	36
125	Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2003, 51, 135-139.	3.0	10
126	Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. Journal of General Virology, 2003, 84, 1431-1436.	2.9	40

#	Article	IF	CITATIONS
127	Phylogenetic Analysis of Rubella Virus Isolated during a Period of Epidemic Transmission in Italy, 1991–1997. Journal of Infectious Diseases, 2003, 187, 1587-1597.	4.0	26
128	Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. Journal of Antimicrobial Chemotherapy, 2003, 52, 324-330.	3.0	29
129	In Vitro Model for the Study of the Dissociation of Increasing Antigenemia and Decreasing DNAemia and Viremia during Treatment of Human Cytomegalovirus Infection with Ganciclovir in Transplant Recipients. Journal of Infectious Diseases, 2003, 188, 1639-1647.	4.0	28
130	Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. Aids, 2003, 17, 1568-1570.	2.2	20
131	Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1. Transplantation, 2003, 75, 1012-1019.	1.0	49
132	Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood, 2003, 101, 5053-5060.	1.4	65
133	Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and non-nucleoside inhibitors in a patient failing highly active antiretroviral therapy. Aids, 2003, 17, 924-927.	2.2	13
134	The Human Cytomegalovirus Ribonucleotide Reductase Homolog UL45 Is Dispensable for Growth in Endothelial Cells, as Determined by a BAC-Cloned Clinical Isolate of Human Cytomegalovirus with Preserved Wild-Type Characteristics. Journal of Virology, 2002, 76, 9551-9555.	3.4	116
135	Emergence of Multiple Drugâ€Resistant Human Cytomegalovirus Variants in 2 Patients with Human Immunodeficiency Virus Infection Unresponsive to Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2002, 34, 1146-1149.	5.8	13
136	Human Cytomegalovirus and Human Umbilical Vein Endothelial Cells: Restriction of Primary Isolation to Blood Samples and Susceptibilities of Clinical Isolates from Other Sources to Adaptation. Journal of Clinical Microbiology, 2002, 40, 233-238.	3.9	26
137	Diagnosis and Outcome of Preconceptional and Periconceptional Primary Human Cytomegalovirus Infections. Journal of Infectious Diseases, 2002, 186, 553-557.	4.0	111
138	Infusion of autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 2002, 99, 2592-2598.	1.4	230
139	Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clinical Microbiology Reviews, 2002, 15, 680-715.	13.6	516
140	Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Research, 2002, 54, 59-67.	4.1	46
141	Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants. Antiviral Research, 2002, 56, 273-278.	4.1	16
142	Lack of transmission to polymorphonuclear leukocytes and human umbilical vein endothelial cells as a marker of attenuation of human cytomegalovirus. Journal of Medical Virology, 2002, 66, 335-339.	5.0	33
143	Transmission of Human Cytomegalovirus from Infected Uterine Microvascular Endothelial Cells to Differentiating/Invasive Placental Cytotrophoblasts. Virology, 2002, 304, 53-69.	2.4	87
144	The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. Journal of General Virology, 2002, 83, 1993-2000.	2.9	30

#	Article	IF	CITATIONS
145	Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. Reviews in Medical Microbiology, 2001, 12, 155-175.	0.9	12
146	Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. Journal of Medical Virology, 2001, 65, 207-217.	5.0	44
147	Higher levels of HIV DNA in memory and naive CD4+ T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. Antiviral Research, 2001, 50, 197-206.	4.1	9
148	Comparative Analysis of Human Cytomegalovirus-Specific CD4+ T-Cell Frequency and Lymphoproliferative Response in Human Immunodeficiency Virus-Positive Patients. Vaccine Journal, 2001, 8, 1225-1230.	2.6	7
149	Declining Levels of Rescued Lymphoproliferative Response to Human Cytomegalovirus (HCMV) in AIDS Patients With or Without HCMV Disease Following Long-Term HAART. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 320-331.	2.1	26
150	Human Cytomegalovirus Immediateâ€Early Messenger RNA in Blood of Pregnant Women with Primary Infection and of Congenitally Infected Newborns. Journal of Infectious Diseases, 2001, 184, 1078-1081.	4.0	40
151	In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. Journal of General Virology, 2001, 82, 1429-1438.	2.9	96
152	Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Research, 2000, 45, 101-114.	4.1	24
153	Higher Short-Term Virologic Efficacy of Three-Class Versus Two-Class Highly Active Antiretroviral Salvage Therapy in HIV-Infected Patients. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 380-384.	2.9	4
154	Human Cytomegalovirus Replicates Abortively in Polymorphonuclear Leukocytes after Transfer from Infected Endothelial Cells via Transient Microfusion Events. Journal of Virology, 2000, 74, 5629-5638.	3.4	145
155	Use of CMV transcripts for monitoring of CMV infections in transplant recipients. International Journal of Antimicrobial Agents, 2000, 16, 455-460.	2.5	7
156	High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders. Journal of Clinical Microbiology, 2000, 38, 613-619.	3.9	156
157	Human Cytomegalovirus Immediate-Early mRNA Detection by Nucleic Acid Sequence-Based Amplification as a New Parameter for Preemptive Therapy in Bone Marrow Transplant Recipients. Journal of Clinical Microbiology, 2000, 38, 1845-1853.	3.9	58
158	Prenatal Diagnostic and Prognostic Value of Human Cytomegalovirus Load and IgM Antibody Response in Blood of Congenitally Infected Fetuses. Journal of Infectious Diseases, 1999, 180, 1320-1323.	4.0	36
159	The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. British Journal of Haematology, 1999, 107, 877-882.	2.5	61
160	Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. Journal of Clinical Virology, 1999, 14, 57-66.	3.1	114
161	HCV genotyping by three methods: analysis of discordant results based on sequencing. Journal of Clinical Virology, 1999, 13, 121-130.	3.1	30
162	Diagnosis and implications of human cytomegalovirus infection in pregnancy. Fetal and Maternal Medicine Review, 1999, 11, 117-134.	0.3	28

#	Article	IF	CITATIONS
163	Quantification of Human Cytomegalovirus DNA in Amniotic Fluid of Mothers of Congenitally Infected Fetuses. Journal of Clinical Microbiology, 1999, 37, 3350-3352.	3.9	80
164	Clinical Significance of Expression of Human Cytomegalovirus pp67 Late Transcript in Heart, Lung, and Bone Marrow Transplant Recipients as Determined by Nucleic Acid Sequence-Based Amplification. Journal of Clinical Microbiology, 1999, 37, 902-911.	3.9	64
165	Circulating cytomegalic endothelial cells are associated with high human cytomegalovirus (HCMV) load in AIDS patients with late-stage disseminated HCMV disease. , 1998, 55, 64-74.		20
166	Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction. Journal of Medical Virology, 1998, 56, 99-103.	5.0	81
167	A novel sensitive assay to define immune status using short-term peripheral blood derived cell culture and dual-color flow cytometry. Immunology Letters, 1998, 62, 45-49.	2.5	3
168	Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised. Journal of Clinical Virology, 1998, 11, 51-60.	3.1	27
169	Short Communication: Geographic and Demographic Differences in the Frequency of Human Cytomegalovirus gB Genotypes 1–4 in Immunocompromised Patients. AIDS Research and Human Retroviruses, 1998, 14, 533-536.	1.1	50
170	Human Cytomegalovirus in Blood of Immunocompetent Persons during Primary Infection: Prognostic Implications for Pregnancy. Journal of Infectious Diseases, 1998, 177, 1170-1175.	4.0	179
171	Interferon-Î ³ Increases Expression of Chemokine Receptors CCR1, CCR3, and CCR5, But Not CXCR4 in Monocytoid U937 Cells. Blood, 1998, 91, 4444-4450.	1.4	74
172	HUMAN CYTOMEGALOVIRUS (HCMV) LEUKODNAEMIA CORRELATES MORE CLOSELY WITH CLINICAL SYMPTOMS THAN ANTIGENEMIA AND VIREMIA IN HEART AND HEART-LUNG TRANSPLANT RECIPIENTS WITH PRIMARY HCMV INFECTION1. Transplantation, 1998, 65, 1378-1385.	1.0	58
173	GANCICLOVIR RESISTANCE AS A RESULT OF ORAL GANCICLOVIR IN A HEART TRANSPLANT RECIPIENT WITH MULTIPLE HUMAN CYTOMEGALOVIRUS STRAINS IN BLOOD1,2. Transplantation, 1998, 66, 324-329.	1.0	74
174	The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients. Antimicrobial Agents and Chemotherapy, 1998, 42, 444-446.	3.2	72
175	Standardization of the Human Cytomegalovirus Antigenemia Assay by Means of In Vitro-Generated pp65-Positive Peripheral Blood Polymorphonuclear Leukocytes. Journal of Clinical Microbiology, 1998, 36, 3585-3589.	3.9	62
176	Rising Levels of Human Cytomegalovirus (HCMV) Antigenemia during Initial Antiviral Treatment of Solid-Organ Transplant Recipients with Primary HCMV Infection. Journal of Clinical Microbiology, 1998, 36, 1113-1116.	3.9	38
177	Comparative quantification of human cytomegalovirus DNA in blood of immunocompromised patients by PCR and Murex Hybrid Captureâ,,¢ System. Clinical and Diagnostic Virology, 1997, 8, 159-165.	1.7	9
178	Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Antiviral Research, 1997, 34, 39-50.	4.1	18
179	Diagnosis of human cytomegalovirus infections in the immunocompromised host. Clinical and Diagnostic Virology, 1996, 5, 181-186.	1.7	12
180	CLINICAL AND VIROLOGICAL MONITORING OF HUMAN CYTOMEGALOVTRUS INFECTION IN 294 HEART TRANSPLANT RECIPIENTS. Transplantation, 1995, 59, 847-850.	1.0	73

#	Article	IF	CITATIONS
181	Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. British Journal of Haematology, 1995, 91, 674-683.	2.5	65
182	Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. Journal of Medical Virology, 1995, 47, 237-244.	5.0	53
183	Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. Journal of Medical Virology, 1995, 47, 462-466.	5.0	82
184	Prenatal diagnosis of congenital human cytomegalovirus infection. Prenatal Diagnosis, 1994, 14, 903-906.	2.3	49
185	Identification of a New VP4 Serotype of Human Rotaviruses. Virology, 1994, 200, 66-71.	2.4	59
186	Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemaia on Patients' outcome. British Journal of Haematology, 1994, 88, 64-71.	2.5	71
187	Prenatal treatment of congenital human cytomegalovirus infection by fetal intravascular administration of ganciclovir. Clinical and Diagnostic Virology, 1993, 1, 61-67.	1.7	36
188	Correlation of quantitative human cytomegalovirus pp65-, p72- and p150-antigenemia, viremia and circulating endothelial giant cells with clinical symptoms and antiviral treatment in immunocompromised patients. Clinical and Diagnostic Virology, 1993, 1, 47-59.	1.7	31
189	Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction. Journal of Virological Methods, 1993, 44, 45-55.	2.1	105
190	Human Cytomegalovirus Infection of the Major Leukocyte Subpopulations and Evidence for Initial Viral Replication in Polymorphonuclear Leukocytes from Viremic Patients. Journal of Infectious Diseases, 1992, 166, 1236-1244.	4.0	183
191	Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Research, 1992, 19, 333-345.	4.1	69
192	Development and evaluation of a capture ELISA for IgM antibody to the human cytomegalovirus major DNA binding protein. Journal of Virological Methods, 1991, 35, 315-329.	2.1	51
193	Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leuckocytes from AIDS patients with human cytomegalovirus viraemia. Molecular and Cellular Probes, 1991, 5, 365-374.	2.1	34
194	Human cytomegalovirus viraemia in HIV-1-seropositive patients at various clinical stages of infection. Aids, 1990, 4, 1027-1032.	2.2	87
195	A 6-hour microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies. Serodiagnosis and Immunotherapy in Infectious Disease, 1990, 4, 243-247.	0.2	17
196	Prevalence of Human Rotavirus Serotypes in Some European Countries 1981–1988. Scandinavian Journal of Infectious Diseases, 1990, 22, 5-10.	1.5	46
197	Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients. Journal of Medical Virology, 1989, 29, 88-93.	5.0	117
198	Determination of coronavirus 229E antibody by an immune-adherence hemagglutination method. Journal of Medical Virology, 1978, 2, 215-223.	5.0	16